The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Charitable donations have been able to fund a specialist chair and two scalp coolers for the Chemotherapy Units at the Cancer ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Henry Ford Health System in Detroit recently provided the first patient in Michigan — a 60-year-old man from the Cadillac ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic ...

A 60-year-old man from the Cadillac area has become the first patient in Michigan to receive a state-of-the-art aerosolized cancer treatment, performed by Henry Ford Health surgical oncologist Dr.